Blood test could spot cancer return months before scans

NCT ID NCT07660627

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a blood test that looks for tiny bits of cancer DNA (ctDNA) in people with esophageal, gastric, or pancreatic cancer. The goal is to see if it can find signs of cancer coming back or getting worse earlier than current methods. About 34 participants will give blood samples before and after treatment to check how well the test works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
deep ctDNA sequencing (blood test)
What this could lead to
If successful, this blood test could help doctors detect cancer relapse or progression earlier than standard scans, allowing for quicker treatment changes.
What could go wrong
This is a small, early-stage study with only 34 participants, so results may not apply to everyone. The test might miss some cancers or give false alarms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Masaryk Memorial Cancer Institute

    RECRUITING

    Brno, 65653, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.